Big Pharma Split Stock Price on October 25, 2024
| PRM Stock | CAD 13.20 0.01 0.08% |
Below is the normalized historical share price chart for Big Pharma Split extending back to November 24, 2017. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Big Pharma stands at 13.20, as last reported on the 11th of December 2024, with the highest price reaching 13.20 and the lowest price hitting 13.20 during the day.
If you're considering investing in Big Stock, it is important to understand the factors that can impact its price. Big Pharma Split secures Sharpe Ratio (or Efficiency) of -0.11, which signifies that the company had a -0.11% return per unit of standard deviation over the last 3 months. Big Pharma Split exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Big Pharma's mean deviation of 0.6695, and Risk Adjusted Performance of (0.09) to double-check the risk estimate we provide.
As of the 11th of December 2024, Liabilities And Stockholders Equity is likely to grow to about 34.5 M, while Total Stockholder Equity is likely to drop about 14.3 M. . At this time, Big Pharma's Price To Sales Ratio is very stable compared to the past year. As of the 11th of December 2024, Price Earnings To Growth Ratio is likely to grow to 0.94, though Price Earnings Ratio is likely to grow to (113.79). Big Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
200 Day MA 14.0842 | 50 Day MA 13.6042 | Beta 0.881 |
Big |
Sharpe Ratio = -0.1082
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PRM |
Estimated Market Risk
| 1.03 actual daily | 9 91% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Big Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Big Pharma by adding Big Pharma to a well-diversified portfolio.
Price Book 0.9426 | Enterprise Value Ebitda (2.45) | Price Sales 46.5157 | Dividend Share 1.237 | Wall Street Target Price 2 |
Big Pharma Valuation on October 25, 2024
It is possible to determine the worth of Big Pharma on a given historical date. On October 25, 2024 Big was worth 13.77 at the beginning of the trading date compared to the closed value of 13.77. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Big Pharma stock. Still, in general, we apply an absolute valuation method to find Big Pharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Big Pharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Big Pharma's related companies.
| Open | High | Low | Close | Volume | |
| 13.90 | 14.00 | 13.75 | 13.75 | 4,062 | |
10/25/2024 | 13.77 | 13.77 | 13.77 | 13.77 | 443.00 |
| 13.66 | 13.66 | 13.55 | 13.66 | 5,500 |
| Backtest Big Pharma | | | Big Pharma History | | | Big Pharma Valuation | Previous | Next |
Big Pharma Trading Date Momentum on October 25, 2024
| On October 28 2024 Big Pharma Split was traded for 13.66 at the closing time. The maximum traded price for the trading interval was 13.66 and the lowest daily price was 13.55 . The daily volume was recorded at 5.5 K. The volume of trading on 28th of October 2024 played a part in the next trading day price drop. The trading delta at closing time to the next closing price was 0.80% . The overall trading delta to the closing price today is 2.11% . |
Big Pharma Split Fundamentals Correlations and Trends
By evaluating Big Pharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Big Pharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Big financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Big Pharma Stock history
Big Pharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Big is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Big Pharma Split will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Big Pharma stock prices may prove useful in developing a viable investing in Big Pharma
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 1.2 M | 1 M | |
| Net Income Applicable To Common Shares | 4.8 M | 5.1 M |
Big Pharma Stock Technical Analysis
Big Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Big Pharma Period Price Range
Low | December 11, 2024
| High |
0.00 | 0.00 |
Big Pharma Split cannot be verified against its exchange. Please verify the symbol is currently traded on Toronto Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Big Pharma December 11, 2024 Market Strength
Market strength indicators help investors to evaluate how Big Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Big Pharma shares will generate the highest return on investment. By undertsting and applying Big Pharma stock market strength indicators, traders can identify Big Pharma Split entry and exit signals to maximize returns
Big Pharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Big Pharma's price direction in advance. Along with the technical and fundamental analysis of Big Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Big to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.30) | |||
| Treynor Ratio | 2.4 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.